

# Design of PCR Primers

```

GGCCTTCTGCTCAATCTTTCTACAACCAAAGCTCTGTCTTGAA
GTCATGGTTGTGGACGATGATCATGTTTTCTTGATATCATGT
GCTTCAACACTCCAAATACAGAGGTAATTAAATATTATTATCA
ATATAATATGTTATTGATTTTTTGTTTGTGATTTCAATTAATTA
CTATGATTTCTTAGCATGAATAACAATTTTGGAGAAACAACT
TTAAAAACAAACTTGAATTTTGAGAAATCAAAGATGTATA
GTCAAAATTAAACAATTATCTTCTAAATCATCCGGATTCCGT
ATACACATCTACAATTTTCAATTGAGGTATCTTGTTTTGATGC
ACGAATAGTTGATTGATAAAAAAATTC TAACCAATATGATA
TTTTTTTCTTTTTGTCAAACCATCTTTATACTATGTA ACTTT
AGATTATTGAAAATAGTTTATTTATAAAA TAGTAACCTA TTGT
AAAAAAAAAAAAAAAATTTGTAAATCGTGTGTTTGCAAACGACATGT
CTTAGTTTAAACTAGCTGATATTCTTCA AATCGACTGTCTT
ATCAACCAATTAGCATCAA TAGAATAAAA TTGTAAACAC TTCA
TGGTGATTTTAAAGAATATGTTTTACTTATGTTATGAAC TATC
TGTGAAATA TTTCATAACTAATGTGGAAA ACTATATAAC CCCT
AAACGTAAGTAAAATTTATGAAATCCTATCATTTTTTAAA GGTT
ATCAAAAAGTATAATTCTTGGTACTTGCAATATTTTTTGT CATT
AGTTTATTAATTTTATTTT GATTAAATGG TTTTAGATCC ATCAG
AGATCGCAGTTATAGCTGTAGACGATCCG AAGAAAGCAT TAT
AAAAATTCAA CGAGACAATA TAGATCTCAT AATCACAGAT TAT
CTGGTATGAA CGGTTTACAACTCAAAAAACAAATCACTCA GGA
AATTTACCGGCTTAGGTAA CTTTTTTGTCTTTACAAC TTA
  
```

Hana Konečná

Proteomics Core Facility

**CEITEC** Central European Institute of Technology

**NCBR** National Centre for Biomolecular Research


# OLIGONUCLEOTIDES

- definition
- applications
- modifications
- synthesis
- purification
- quality control


- design of sequence
- rules
- software OLIGO 7
- example

# oligonucleotide

- short single stranded structure
- DNA or RNA (also PNA)
- **hydroxyl** on both ends  
(no phosphate on 5-end as usual)



orientation! polymerase!




# Applications of synthetic oligonucleotides

- primers for synthesis of complementary DNA  
*PCR, Real-Time PCR*
- gene synthesis and recombinant proteins
- hybridisation probes for cloning
- site directed mutagenesis
- sequencing and genetic profiling
- diagnostics – tests and biosensors
- gene arrays
- blockage of gene expression *antisense oligo*
- prospective therapeutics and DNA vaccines
- NMR monitoring of DNA – protein interactions
- structural X-ray analysis of NA

# Modifications

- degeneration
- end of sequence
- bases
- phosphate
- carbohydrate
- PNA



# Degenerated oligonucleotides

Examples:

ACG TAC GTA CGT ACG TAC      non-degenerated

ACG TAM GTA CGT ACG TAC      M = A/C

ACG TAC GTA CDT ACG TAC      D = A/G/T

ACG TAC GTA CGT ACG NAC      N = A/C/G/T

# Degenerated oligonucleotides

2-deoxyinosin

<b>M</b>	A or C
<b>R</b>	A or G
<b>W</b>	A or T
<b>S</b>	C or G
<b>Y</b>	C or T
<b>K</b>	G or T
<b>V</b>	A or C or G
<b>H</b>	A or C or T
<b>D</b>	A or G or T
<b>B</b>	C or G or T
<b>N</b>	G or A or T or C
<b>X</b>	G or A or T or C

# Modification on 5' - end

postsynthetic modifications



sequencing  
fragmentation analysis  
gene arrays  
Real-Time PCR



Phosphorylation  
Amino group  
Thio group  
Digoxigenin  
Biotin  
Enzymes  
Psoralen  
Acridine  
Cholesterol  
Fluorescent dyes  
Quenchers  
2,4- dinitrophenyl  
Spacer  
Branching  
Block



# Modifications on 3'-end

derivatized matrix



Phosphate  
Thio group  
Amino group  
Spacer



Biotin



Fluorescent dyes




Quenchers

Cholesterol


2,4 dinitrophenyl

# Real-Time PCR


- 2x labeled probe
- REPORTER
- QUENCHER




2. **Strand displacement:** When the probe is intact, the reporter dye emission is quenched.



3. **Cleavage:** During each extension cycle, the DNA polymerase cleaves the reporter dye from the probe.



4. **Polymerization completed:** Once separated from the quencher, the reporter dye emits its characteristic fluorescence.



# Other modifications

Phosphorothioates  
Phosphorodithioates  
H-phosphonates  
Methylphosphonates


← backbone

carbohydrate →


Modifications in 2' - position  
Ribose modification

# Therapeutics


→ **Nondegradable by nucleases!**  
Modification of phosphodiester




phosphorothioate




methylphosphonate




phosphoramidate



3'-thioformacetal




methylene(methyliminio)



boranophosphate

# ANTISENSE oligonucleotide



- oligonucleotide or analogue
- complementary to segment of RNA or DNA
- inhibition of normal function due to coupling



# Peptidonucleic acid

- uncharged molecule
- binding with DNA/RNA



N-(2-aminoethyl)-glycine →



# Peptidonucleic acid

- noncharged molecule
- binding with DNA/RNA

N-(2-aminoethyl)-glycine →



# Why PNA

- thermostable
- $T_m$  not depending on salts
- high specificity
- high affinity
- resistant towards enzymes

Gambari R. *Expert Opin Ther Pat.* 2014, 24(3):267-94.


Peptide nucleic acids: a review on recent patents and technology transfer.



# LNA

## Locked Nucleic Acid

- 2'-O, 4'-C methylene bridge
- suppressed flexibility of ribofuranose ring
- structure is locked into rigid C3-endo conformation
- enhanced hybridisation
- outstanding biostability



*Molecular Therapy* (2012); **20** 8, 1590–1598.

**LNA-based Oligonucleotide Electrotransfer for miRNA Inhibition**

# OLIGONUCLEOTIDES

design

synthesis


purification




**EXPEDITE 8909**

# Oligonucleotide Synthesis

- synthesis on solid matrix
- from 3'-end to 5'-end
- anhydrous environment



# Quality Control




- HPLC
- perfusion chromatography



- anex
- RP

# Perfusion chromatography

classical sorbent




POROS




# Quality Control


Maldi-TOF MS



CE




# YIELD



## Efficiency

- 0.995
- 0.990
- 0.980


## PAGE of long-mers



85 85 75 75 65 65  
crude purified crude purified crude purified

# PURIFICATION

- Sephadex
- RP cartridge
- HPLC






## OLIGONUCLEOTIDE DESIGN

- manual
- computer assisted

[www.protocol-online.org/prot/Research\\_Tools/Online\\_Tools/Oligo\\_Design/index.html](http://www.protocol-online.org/prot/Research_Tools/Online_Tools/Oligo_Design/index.html)

## Main features of good PCR primer sequence

- highly specific
- no dimers and hairpins
- stable duplexes with active sequence
- lightly unstable 3'-end



## OLIGO 6

- PCR primers
- hybridisation probes
- sequencing primers

## OLIGO 7 (from 2008)

- TaqMan probes
- primers for *nested PCR*
- *molecular beacons*
- siRNA


# Terminology of PCR primers

forward primer... part of the **+ string**

reverse primer... part of the **- string**




UPPER - FORWARD - LEFT



# Terminology

forward primer... part of the + string


reverse primer... part of the - string



# Annealing of PCR primers



UPPER - FORWARD - LEFT



LOWER - REVERSE - RIGHT

5' CTT CTG CTC AAT CTT TCT AC 3' FORWARD

+ 5'

1 ATGG CTTCTG CTCAATCTTT C ACAACCAA AGCTCTGTCT TGAAAATCAA  
 51 TGTCATGGTT GTGGACGATG ATCATGTTTT CCTTGATATC ATGTCACGCA  
 101 TGCTTCAACA CTCCAAATAC AGAGGTAATT AAATATTATT ATCATATTAT  
 151 ATATAATATG TTATTGATTT TTTGTTTGTG ATTTCAATTA GATTTTTATT  
 201 TCTATGATTT CTTAGCATGA AATACAATTT TTGGAGAAAC AACTAGCAGT  
 251 TTTAAAAACA AAAC TTGAAT TTTGAGAAAT TCAAAGATGT TATATATATA  
 301 TGTCAA AATT TAACAATTAT TCTTCTAAAT CATCCGGATT CCGTTTACAT  
 351 GTACACATCT ACAATTTTCA ATTGAGGTAT TCTTGTTTTG ATGCCTTTGA  
 401 GACGAATAGT TTGATTGATA AAAAAAATTC TAACCAATAT GATATATAAA  
 451 GTTTTATTTTC TTTTTGTCAA ACCATACTTT ATACTATGTA ACTTTTTTAA  
 501 GAGATTATTG AAAATAGTTT ATTTATAAAA TAGTAACCTA TTGTTGAATT  
 551 AAAAAAAAAA AAAAAATTGT AAATCGTGTG TGCAAACGAC ATGTGATTTA  
 601 TCTTAGTTTA AAAC TAGCTG ATATTCT CA AATCGACTGT TCTTATAAGT  
 651 AATCAACCAA TTAGCATCAA TCACAATAAA TTGTAAACAC TTCAATGAAA  
 701 ATGGTGATTT TAAAGAATAT GTTTTACTTA TGTTATGAAC TATCTCAAAT  
 751 TTGTGAAATA TTTCATAACT AATGTGGAAA ACTATATAAC CCCTCCATAC  
 801 AAAACGTAAG TAAAATTTAT GAAATCCTAT CATTTTTTAAA GGTAAACCA  
 851 ATCAAAAAGT AATAATTCTT GGTACTTGCA ATATTTTTGT CATTATATTT  
 901 TAGTTTATTA ATTTTATTTT GATTAAATGG TTTTAGATCC ATCAGTTATG  
 951 GAGATCGCAG TTATAGCTGT AGACGATCCG AAGAAAGCAT TATCTACTCT  
 1001 AAAAATTCAA CGAGACAATA TAGATCTCAT AATCACAGAT TATTATATGC  
 1051 CTGGTATGAA CGGTTTACAA CTCAAAAAAC AAATCACTCA GGAATTTGGA  
 1101 AATTTACCGG TCTTAGGTAA CATTTTTTGT TCTTTACAAC TTA AATTAAA

3'

5' TGA AGA ATA TCA GCT AGT TT 3' REVERSE



### Search for Primers & Probes

**Search Options** | Subsearches

Search in:  + Strand  - Strand  
Search Mode:  Select  Verify

Complex Substrate




PCR Primers  
Compatible with the  Forward Primer  Reverse Primer

TaqMan Probes & PCR Pairs  
Compatible with the  Upper Probe  Lower Probe


Molecular Beacons & PCR Pairs  
 Nested Primers  
 Sequencing Primers  
 Hybridization Probes  
 siRNA Probes

After successfull search show: All Results

Search  
Cancel  
Apply  
Parameters  
Ranges  
Defaults








## PCR

File: Human 4E.seq



Optimal Annealing Temperature: 50.8 °C (Max: 66.3 °C)

	Position and Length	$T_m$ [°C]	GC [%]	P.E.#	Score
Product	862	78.9	29.6	n/a	697
Forward Primer	918 22	56.9	45.5	471 / 471	840
Reverse Primer	1753 27	55.3	29.6	489 / 489	834
Upper Oligo	979 24	56.5	33.3	479 / 479	917
Lower Oligo	1694 23	55.4	39.1	457 / 457	841

Product  $T_m$  - Reverse Primer  $T_m$  : 23.6 °C

Primers  $T_m$  difference: 1.6 °C

Comments:

	Concentration	
Forward Primer	200.0	nM
Reverse Primer	200.0	nM
Upper Oligo	200.0	nM
Lower Oligo	200.0	nM
Monovalent Cation	50.0	mM
Free Mg[2+]	0.7	mM

Total Na[+] Equivalent: 155.8 mM

### Selected Primers

File: BRCA2 gene.seq

AY436640:15438F22

5' CAATATATACCGTAGTCCCCTA 3'

Length:	22-mer	
Score:	802 points	
5' Position:	15438	
$T_m/t_m$ :	53.4	52.6 °C
$\Delta G/\Delta g$ (25 °C):	-30.5	-29.2 kcal/mol
$\Delta S/\Delta s$ :	-472.1	-449.5 cal/°K * mol
$\Delta H/\Delta h$ :	-171.3	-163.2 kcal/mol
3' $\Delta G$ :	-6.5 kcal/mol	
Degeneracy:	1	
P.E.#:	443/443	
1/E:	4.63 nmol/A <sub>260</sub>	31.1 µg/A <sub>260</sub>

AY436640:15917R20

5' CAGCTACATATTACGCCAGA 3'

Length:	20-mer	
Score:	914 points	
3' Position:	15917	
$T_m/t_m$ :	53.1	53.8 °C
$\Delta G/\Delta g$ (25 °C):	-28.6	-28.5 kcal/mol
$\Delta S/\Delta s$ :	-430.5	-419.6 cal/°K * mol
$\Delta H/\Delta h$ :	-157.0	-153.6 kcal/mol
3' $\Delta G$ :	-6.9 kcal/mol	
Degeneracy:	1	
P.E.#:	477/477	
1/E:	5.05 nmol/A <sub>260</sub>	31.0 µg/A <sub>260</sub>

Priming Efficiency PE  
Score

# Secondary structures


- HAIRPIN intramolecular
- DIMER intermolecular

## Current Oligo Duplexes


File: BRCA2 gene.seq

Current Oligo 21-mer [5042]


[Current+ Oligo] - The most stable 3'-dimer: # of hydrogen bonds = 10;  $\Delta G = -0.7$  kcal/mol




[Current- Oligo] - The most stable 3'-dimer: # of hydrogen bonds = 10;  $\Delta G = -7.3$  kcal/mol;  $T_m = 2.9^\circ\text{C}$



The most stable dimer overall: # of hydrogen bonds = 10;  $\Delta G = -7.4$  kcal/mol;  $T_m = 2.2^\circ\text{C}$



Hairpin: loop = 5 nt;  $\Delta G = -3.0$  kcal/mol;  $T_m = 54.6^\circ\text{C}$






## Current Oligo Hairpin Stems


File: BRCA2 gene.seq

Current Oligo 21-mer [5042]


1. # of paired bases = 5; loop = 5 nt;  $\Delta G = -3.0$  kcal/mol;  $T_m = 54.6$  °C



2. # of paired bases = 6; loop = 5 nt;  $\Delta G = 0.2$  kcal/mol;  $T_m = 21.7$  °C



3. # of paired bases = 4; loop = 2 nt;  $\Delta G = 0.9$  kcal/mol;  $T_m = 8.7$  °C



Reverse Primer False Priming Sites

File: M13MP18

Reverse Primer M13MP18:6310R19 (positive strand)  
Priming efficiency of the perfect match is 482 (above the threshold)

Priming efficiency: 482 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (6328) ccaaaagggtcagtgctgc (6310)5'
  
```

Priming efficiency: 244 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (626)  agcaaatggtc--tgctgc (610)5'
  
```

Priming efficiency: 193 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (5125) tctaagtggtcagtg-tgc (5108)5'
  
```

### Forward Primer Composition

File: BRCA2 gene.seq

Forward Primer AY436640:6275F19

$T_d$	64.2°	[nearest neighbor method]
$T_m$	56.5°	[nearest neighbor method]
$T_m$	70.8°	[%GC method]
$T_m$	56°	[2(A+T)° + 4(G+C)° method]
$T_m$ (RNA)[1M Na]	81°	[%GC method]
$T_m$ (DNA:RNA)[1M Na]	74.7°	[%GC method]
$A_{260}/A_{280}$	1.59	[single strand]
Molecular Weight	5.8K	[one strand]
Molecular Weight	11.7K	[two strands]
$\mu\text{g}/\text{OD}$	47.4	[dsDNA]

Base	Number	%
A	2	[10.5%]
C	5	[26.3%]
G	4	[21.1%]
T	8	[42.1%]
A + T	10	[52.6%]
G + C	9	[47.4%]

### Oligonucleotide Database

File: NewDatabase.odb

# of Records: 29

#	Date	ID Number	Sequence	3'-Dim. ΔG		P.E. / p.e.		Tm / t <sub>m</sub>	
<input type="checkbox"/> 21	12/02/06	AY436640:5916R19	AATGCCTGCCTTTAGTCTG	-	SC	430	430	54.1	54.5
<input type="checkbox"/> 22	12/02/06	AY436640:5916R20	CAATGCCTGCCTCTAGTCTG	0.3	SC	366	450	50.9	57.2
<input type="checkbox"/> 23	12/02/06	AY436640:5937R21	TCAATTTCTTTAGCTTGGCAT	0.3	SC	449	449	54.7	53.1
<input checked="" type="checkbox"/> 24	12/02/06	AY436640:5937R22	TTCAATTTCTTTAGCTTGGCAT	0.3	SC	458	458	55.9	53.8
<input type="checkbox"/> 25	12/02/06	AY436640:4695U22	TGCCTTAACAAAAGTAATCCAT	0.3	SC	432	432	54.5	53.0
<input type="checkbox"/> 26	12/02/06	AY436640:5325U22	AATTACGTCTTTCTTATGCCAA	0.3	SC	453	453	53.3	53.0
<input type="checkbox"/> 27	12/02/06	AY436640:5786L23	CTCTGCCTAGAACATTATCACTC	-0.3	SC	451	451	54.8	55.0
<input type="checkbox"/> 28	12/02/06	AY436640:5860L19	AACAACCAAAGCCAACCTG	-0.9	SC	444	444	55.3	55.9

Selected oligo

#### Oligonucleotide Sets (64)

#	Forward Primer	Reverse Primer	Upper Oligo	Lower Oligo
1	2	3	4	
<input type="checkbox"/> 36	8	23	25	28
<input type="checkbox"/> 42	8	24	25	28
<input checked="" type="checkbox"/> 47	9	14	25	27
<input type="checkbox"/> 39	9	15	25	27
<input type="checkbox"/> 33	9	16	25	27
<input type="checkbox"/> 61	9	17	25	27
<input type="checkbox"/> 48	9	18	25	27

Checked Set of nested primers

This database is linked to BRCA2 gene.seq





### Restriction Enzyme Sites in Protein

File: BRCA2 gene.seq



#	Enzyme	Site	# Cuts	Positions & Fragment Sizes
41	KpnI	GT2VpzY6	8	-21253 23654 68 23722 52 23774 237 24011 585 24596 162 24758 629 25387 1219 26606 22851
42	MluI	TR1RVyA7	5	-22233 22674 2824 25498 576 26074 106 26180 244 26424 23033
43	MunI	QL3NawI5	10	-21287 23620 355 23975 351 24326 282 24608 242 24850 72 24922 351 25273 714 25987 187 26174 420 26594 22863
44	NaeI	AG2PAxR6	7	-21823 23084 597 23681 1286 24967 86 25053 573 25626 149 25775 623 26398 23059
45	NarI	GA2APzR6	1	-20043 24864 24593
46	NcoI	PW3HGwM5	4	-22361 22546 336 22882 887 23769 531 24300 25157
47	NdeI	HM2IawY5	2	-20366 24541 1211 25752 23705
48	NheI	AS2Lax-6	16	-22276 22631 322 22953 185 23138 88 23226 27 23253 461 23714 369 24083 312 24395 288 24683 151 24834 273 25107 536 25643 402 26045 30 26075 210 26285 372 26657 22800

Search: 22454 to 27004 End Cut Type: Blunt, Odd, 3'-overhang, 5'-overhang


## Hybridization Time

File: M13MP18

DNA Length:  nt.

Concentration:  nM

$\mu\text{g/mL}$



$T_{1/2} = 45.4 \text{ sec}$

$T = 3 \text{ min } 47 \text{ sec}$

## Concentrations

File: BRCA2 gene.seq

Constant Concentration
  Constant Volume

- Current +Oligo: 5.08 nmol/OD, 32.5 µg/OD
- Current -Oligo: 4.67 nmol/OD, 30.9 µg/OD
- Entire Sequence (ds): 0.001 nmol/OD, 48.1 µg/OD
- Forward Primer: 5.98 nmol/OD, 35.0 µg/OD
- Reverse Primer: 5.31 nmol/OD, 34.0 µg/OD
- PCR Product (ds): 0.146 nmol/OD, 48.1 µg/OD
- Upper Oligo: 4.83 nmol/OD, 31.2 µg/OD
- Lower Oligo: 4.67 nmol/OD, 30.9 µg/OD

µg  
 or  OD(260)  
 or  nmol  
 in  µL  
 yields  µM

## AHP2 cDNA (TAIR database)

**Sequence: AT3G29350.1** Date last modified 2007-04-17 Name AT3G29350.1 Tair  
Accession Sequence:4010737427 Sequence Length (bp) 827

```

1 ACAATTCGCG AGAAAGACAA AACACAAGTT TCTTCTTCTT GGGATTGGCT
51 ATTTCCAGAA ATCCAAGTCA ATAATCAAAG TCCAACAAA AAAATCCTCT
101 CCCAATCTCC GCTTCACTCT TCTCATGGAC GCTCTCATTG CTCAGCTTCA
151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA ACTAAAGAGA
601 CTAGTCCATA AGAAGAAAAA AGATGATGAC TTTCTTTCTT TAGTTTCTCT
651 TCTAAATTAT TTTGGATTTG GTGTTTGCTC AAAAACTCAA TAAAATATGT
701 GCAAAAAGAA ACAAAAACAA GTGATGGTTG TTTATAAATC AGTAGTATGT
751 ATTGTTTGAT CTCATCCGAG AAAATTGAAA CCATTGGACT AATGAATGTG
801 ATGATAATAT ATATTGGTTT GCTTCTG

```

101 CCCAATCTCC GCTTCACTCT TCTCATGGAC GCTCTCATTG CTCAGCTTCA  
 151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG  
 201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT  
 251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT  
 301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC  
 351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT  
 401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC  
 451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT  
 501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACA  
 551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA ACTAAAGAGA

### EcoRI restriction site

5'.....G|AATTC.....3'

3'.....CTTAA|G.....5'

|

### Design of primers

#### AHP2ex\_up

5'- CCG **GAA TTC** ATG GAC GCT CTC ATT GCT CAG – 3'

#### AHP2ex\_low

5'- CCG **GAA TTC** TTA GTT AAT ATC CAC TTG AGG – 3'

101 CCCAATCTCC GCTTCACTCT TCTC **ATGGAC GCTCTCATTG CTCAGCTTCA**  
 151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG  
 201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT  
 251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT  
 301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC  
 351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT  
 401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC  
 451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT  
 501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG  
 551 ATCATTCAAG CTGGTGGTAT AGTT **CCTCAA GTGGATATTA ACTAA**AGAGA

### EcoRI restriction site

5'.....G|AATTC.....3'

3'.....CTTAA|G.....5'

|

### Design of primers

#### AHP2ex\_up

5'- CCG **GAA TTC** ATG GAC GCT CTC ATT GCT CAG – 3'

#### AHP2ex\_low

5'- CCG **GAA TTC** TTA GTT AAT ATC CAC TTG AGG – 3'

## LITERATURE

- Artificial DNA: Methods and Applications; Khudyakov, Y.E., Fields, W.A., Ed. (2003)
- PCR Primer: A Laboratory Manual (2003)
- OLIGO Primer analysis software, Version 7
- *Expert Opin Ther Pat.* 2014, 24(7):801-19.  
Oligonucleotide delivery: a patent review (2010 - 2013).
- *AAPS Journal* 2009, 11(1): 195 - 203.  
Targeted Delivery Systems for Oligonucleotide Therapeutics
- Large-scale de novo DNA synthesis: technologies and applications  
*Nature Methods* 2014, 11 (5): 499

## Other resources

AutoDimer (Vallone and Butler, 2004). <http://www.cstl.nist.gov/strbase/NIJ/AutoDimer.htm>

CODEHOP (Rose et al., 2003; Boyce et al., 2009). <https://icodehop.cphi.washington.edu/i-codehop-context/Welcome>

HYDEN (Linhart and Shamir, 2002; 2005). <http://acgt.cs.tau.ac.il/hyden/HYDEN.htm>

JCVI Primer Designer (Li et al., 2008). <http://sourceforge.net/projects/primerdesigner/>

MAD-DPD (Najafabadi et al., 2008). [http://bioinf.cs.ipm.ir/download/MAD\\_DPD08172007.zip](http://bioinf.cs.ipm.ir/download/MAD_DPD08172007.zip)

MIPS (Souvenir et al., 2003; 2007). <http://www.cs.wustl.edu/%7Ezhang/projects/mips.zip>

NetPrimer. <http://www.premierbiosoft.com/netprimer/index.html>

OLIGO. <http://www.oligo.net/>

PAMPS (Najafabadi et al., 2008). <http://www.biomedcentral.com/content/supplementary/1471-2105-9-55-S1.zip>

Primer3 (Rozen and Skaletsky, 2000). <http://frodo.wi.mit.edu/primer3/>

Primer3Plus (Untergasser et al., 2007). <http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi>

PrimerStation (Yamada et al., 2006) <http://ps.cb.k.u-tokyo.ac.jp>

Pythia (Mann et al., 2009). <http://frodo.wi.mit.edu/primer3/>

ThermoBLAST™. <http://dnasoftware.com/tabid/110/Default.aspx>

UNAFold (Mfold<sup>++</sup>, Markham and Zuker, 2008). <http://dinamelt.bioinfo.rpi.edu/download.php> <http://mfold.bioinfo.rpi.edu/>

Vector NTI<sup>®</sup>. <http://www.invitrogen.com/site/us/en/home/LINNEA-Online-Guides/LINNEA-Communities/Vector-NTI-Community/Vector-NTI.html>

Visual OMP™. <http://dnasoftware.com/tabid/108/Default.aspx>





Discovery is not in seeking new landscapes,  
but in having new eyes...

Marcel Proust